LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
26 funds hold it · Insiders net selling
Net selling: insiders sold $12.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.03 expected
Estimates as of Nov 10, 2026
EPS expected
$0.05 to $0.19
Revenue expected
8 analysts
Last 30 days
Analysts raising estimates
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 4, 2026 | $0.05est. $0.03 | +$0.02beat | $275.4MSEC filing | +27.0%from $216.8M |
| Jun 30, 2026Reported Aug 5, 2026 | -$0.54est. -$0.01 | -$0.53miss | $263.7MSEC filing | +45.4%from $181.4M |
| Mar 31, 2026Reported May 7, 2026 | -$0.00est. -$0.02 | +$0.02beat | $216.2MAlpha Vantage | +78.8%from $120.9M |
| Dec 31, 2025Reported Feb 26, 2026 | $0.28est. $0.01 | +$0.27beat | $292.9MAlpha Vantage | No year-ago quarter |
| Sep 30, 2025Reported Nov 5, 2025 | $0.08est. -$0.08 | +$0.16beat | $216.8MSEC filing | No year-ago quarter |
| Jun 30, 2025Reported Aug 12, 2025 | -$1.11est. -$0.22 | -$0.89miss | $181.4MSEC filing | No year-ago quarter |
| Mar 31, 2025Reported May 28, 2025 | -$0.35Reported | No estimate | $120.9MAlpha Vantage | No year-ago quarter |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $292.9M | $216.2M | $263.7M | $275.4M |
| Cost of what it sold | $72.0M | $74.8M | $84.1M | $93.1M |
| Gross profit | $220.9M | $141.3M | $179.6M | $182.3M |
| What it spent | ||||
| Research and development | $31.8M | $5.4M | $32.4M | $33.8M |
| Sales and admin | $56.5M | $59.7M | $66.5M | $69.3M |
| Other operating costs | $44.2M | $71.0M | $53.8M | $59.9M |
| Total operating expenses | $132.5M | $136.1M | $152.7M | $163.0M |
| What was left | ||||
| Operating profit | $88.4M | $5.3M | $26.9M | $19.3M |
| Interest on debt | $11.4M | $12.8M | $9.2M | $9.2M |
| Profit before tax | $82.0M | -$644.0K | -$614.0K | $16.9M |
| Tax | — | -$134.0K | $23.0K | $1.6M |
| Net profit | $82.0M | -$510.0K | -$637.0K | $15.3M |
| EBITDA | $97.6M | $17.2M | $15.2M | $26.1M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
FMR LLC and Abigail P. Johnson Reveal 13.4% Ownership Stake in Caris Life Sciences
BullishNov 5Zero voting power accompanies Abigail P. Johnson's stake in Caris Life Sciences (CAI).
NeutralNov 535 macro signals shaping CAI right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
